Alpelisib, a PI3K inhibitor, is approved for patients with HR+, HER2- and PIK3CA-mutated cancers in combination with fulvestrant [6], while the PARP inhibitor olaparib targets BRCA mutations in early breast cancer [7]. The gene discussed is ERBB2; the disease is breast carcinoma.